Endocannabinoid signaling in reward and addiction.

ARTICLE in NATURE REVIEWS NEUROSCIENCE · SEPTEMBER 2015

Impact Factor: 31.43 · DOI: 10.1038/nrn4004

2 AUTHORS, INCLUDING:

Loren H Parsons
The Scripps Research Institute

118 PUBLICATIONS  8,343 CITATIONS

Available from: Loren H Parsons
Retrieved on: 23 September 2015
Endocannabinoid signalling in reward and addiction

Loren H. Parsons1 and Yasmin L. Hurd2

Abstract | Brain endocannabinoid (eCB) signalling influences the motivation for natural rewards (such as palatable food, sexual activity and social interaction) and modulates the rewarding effects of addictive drugs. Pathological forms of natural and drug-induced reward are associated with dysregulated eCB signalling that may derive from pre-existing genetic factors or from prolonged drug exposure. Impaired eCB signalling contributes to dysregulated synaptic plasticity, increased stress responsiveness, negative emotional states and cravings that propel addiction. Understanding the contributions of eCB disruptions to behavioural and physiological traits provides insight into the eCB influence on addiction vulnerability.

The brain reward system is critical for survival. The hedonic effects produced by eating, exercise and sexual activity provide important motivational effects that increase the likelihood of future engagement in these critical activities (that is, positive reinforcement). The reward system is also essential for important negative hedonic responses, in which aversive or unpleasant events (for example, sickness or bodily harm) increase the likelihood of behaviours that will avoid or relieve these negative states (that is, negative reinforcement).

Seminal discoveries demonstrating that the effects of marijuana (*cannabis sativa*) are mediated by cannabinoid receptors in the brain propelled significant research initiatives that expanded our knowledge about the body’s endogenous cannabinoid system (termed the endocannabinoid (eCB) system (ECS)), which is now acknowledged to have a prominent role in modulating brain reward function and maintaining emotional homeostasis. This Review examines the evidence for an eCB influence in the positive-reinforcing effects of natural rewards and drugs of abuse. In contrast to the initial plausible experience of rewarding stimuli, prolonged drug exposure contributes to aberrant synaptic plasticity, negative emotional states and impaired learning and memory processes that sustain compulsive drug consumption, which is characteristic of the addicted state. We explore the ECS signalling underlying these maladaptive processes and provide an overview of the existing literature regarding the genetic factors that are associated with the ECS to gain insight about the potential contribution of ECS signalling dysregulation to addiction disorders.

The ECS and reward circuits

The ECS comprises G protein-coupled receptors and small neuromodulatory lipid ligands, as well as biosynthetic and metabolic enzymes for the synthesis and degradation of the ligands, respectively. Two major types of cannabinoid receptor have been characterized and cloned: cannabinoid 1 receptors (CB1Rs; encoded by *CNR1*) and CB2Rs (encoded by *CNR2*). CB1Rs are the most-abundant G protein-coupled receptors that are expressed in the adult brain, and they show particularly dense expression in regions that have a known involvement in reward, addiction and cognitive function, including the amygdala, cingulate cortex, prefrontal cortex (PFC), ventral pallidum, caudate putamen, nucleus accumbens (NAc), ventral tegmental area (VTA) and lateral hypothalamus1,2. CB2Rs are expressed mainly by immune cells, although recent evidence suggests that such receptors are also expressed in neurons, glia and endothelial cells in the brain1. CB1Rs and CB2Rs are coupled to similar transduction systems, primarily through G,3,4,5 proteins. CB1Rs directly inhibit the release of GABA, glutamate and acetylcholine, which produce widespread effects on neural signalling across many neurotransmitter systems.

To date, the best-characterized eCB ligands are N-arachidonylthanolamide (anandamide (AEA)) and 2-arachidonoylglycerol (2-AG). Owing to their lipid nature, AEA and 2-AG are not stored in vesicles but are synthesized on demand by cleavage of membrane precursors and immediate release through Ca2+-dependent mechanisms. AEA is derived from the phospholipid precursor N-arachidonoyl-phosphatidylethanolamine.

---

1 Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
2 Friedman Brain Institute, Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York City, New York 10029, USA.

E-mail: lparsons@scripps.edu, yasmin.hurd@mssm.edu

Published online

16 September 2015
are also innervated

biosynthetic and hydrolytic enzymes is generally conserved throughout the brain. AA, mechanisms are depicted here in the VTA, the pre- and postsynaptic organization of eCB signalling is initiated by cellular reuptake followed by (CB1R) neurons in the ventral tegmental area (VTA), opposite cannabinoid 1 receptor DAGL-specific phospholipase D, most memory and olfaction.

DAGL is found on the plasma membranes of both dopaminergic and non-dopaminergic neurons in the ventral tegmental area (VTA), opposite cannabinoid 1 receptor (CB1R)-expressing glutamate and GABA axon terminals. Termination of endocannabinoid (eCB) signalling is initiated by cellular reuptake followed by enzyme-mediated hydrolytic cleavage. 2-AG hydrolysis is primarily mediated by presynaptic monoacylglycerol lipase (MAGL), although postsynaptic enzymes, including α,β-hydrolyase 6 (ABHD6), also contribute to 2-AG clearence. AEA hydrolysis occurs in postsynaptic cells through fatty acid amide hydrolase (FAAH). Although these mechanisms are depicted here in the VTA, the pre- and postsynaptic organization of eCB biosynthetic and hydrolytic enzymes is generally conserved throughout the brain, AA, arachidonic acid.

**Endocannabinoid biosynthesis, signalling and clearance.** The most commonly accepted route for N-arachidonylethanolamide (anandamide (AEA)) synthesis is from catalysis of N-arachidonoyl-phosphatidylethanolamine (NAPE) via a specific phospholipase D, N-acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD). 2-arachidonoylglycerol (2-AG) derives from the hydrolysis of 1,2-diacylglycerol (DAG) via the sn-1-selective DAG lipases (DAGLα and DAGLβ). DAGLα is found on the plasma membranes of both dopaminergic and non-dopaminergic neurons in the ventral tegmental area (VTA), opposite cannabinoid 1 receptor (CB1R)-expressing glutamate and GABA axon terminals. Termination of endocannabinoid (eCB) signalling is initiated by cellular reuptake followed by enzyme-mediated hydrolytic cleavage. 2-AG hydrolysis is primarily mediated by presynaptic monoacylglycerol lipase (MAGL), although postsynaptic enzymes, including α,β-hydrolyase 6 (ABHD6), also contribute to 2-AG clearence. AEA hydrolysis occurs in postsynaptic cells through fatty acid amide hydrolase (FAAH). Although these mechanisms are depicted here in the VTA, the pre- and postsynaptic organization of eCB biosynthetic and hydrolytic enzymes is generally conserved throughout the brain, AA, arachidonic acid.

**Limbic system**
A collection of brain structures that includes the amygdala, hippocampus, limbic cortex, limbic midbrain areas and anterior thalamic nuclei, regulates autonomic and endocrine function and participates in the control of emotion, motivation, long-term memory and olfaction.

**Neurobiology of reward**
Mesocorticolimbic dopamine (DA) pathways, which arise from the midbrain VTA, have a critical role in the mediation of reward. In particular, the VTA DA projection to the NAC (part of the ventral striatum) has a prominent role in positive reinforcement (FIG. 2), that is, the recognition of rewards in the environment and promotion of goal-directed behaviour (approach behaviour), resulting in reward acquisition. Natural rewards, such as food, sex and exercise, and drugs of abuse — including psychostimulants (such as cocaine and amphetamine), nicotine, alcohol, opiates and cannabinoids — increase NAc DA levels, and this neurochemical response contributes to subjective reward and positive reinforcement. Components of the limbic system are also innervated by VTA DA neurons, including the amygdala, hippocampus, orbitofrontal cortex and parts of the PFC.

These regions are interconnected in complex circuits that involve excitatory (primarily glutamatergic) and inhibitory (primarily GABAAergic) projections. In broad, simplistic terms, amygdala circuits contribute to the formation of associative reward- and fear-related memories, hippocampal circuits are critical for declarative memory functions and frontal cortical circuits mediate control of executive functions. In turn, innervation of the NAc by each of these circuits allows sensory and emotional information to be converted into motivational actions through the output to extrapyramidal motor systems. DA signalling in the dorsal striatum does not have a major influence in processing acute reward but has a key role in the development of compulsive forms of reward seeking and consumption.

These same circuits participate in negative-reinforcement mechanisms that promote behaviours for avoiding or relieving aversive states. In general, NAC DA levels are decreased by aversive conditions, such as unavoidable shock, chronic pain, certain patterns of over- or under-eating and withdrawal from addictive drugs, and the resultant increased activity of medium spiny output neurons contributes to aversive states. Negative-reinforcement mechanisms associated with abstinence from long-term access to palatable food or abused drugs are mediated in part by excessive influence of pro-stress signalling systems (such as corticotropin-releasing factor and dynorphin) and impaired function of anti-stress signalling systems (such as neuropeptide Y and nociceptin) in stress circuits that involve the central nucleus of the amygdala (CeA), bed nucleus of the stria terminalis (BNST), frontal cortex and medial shell of the NAc. Thus, reward processing is mediated in large part through an interconnected network of structures, including the VTA, NAc, ventral pallidum, CeA, BNST and PFC. In addition to the well-known involvement of DA described above, reward processing is heavily influenced by many other systems, including the cholinergic, opioid peptide, glutamatergic and GABAAergic systems.

CB1Rs are present in each of the interconnected structures involved in reward, where they exert widespread modulatory influences on excitatory and inhibitory signalling in a manner that influences reward processing. In particular, eCBs have a prominent role in...
interactions between the ECS and other signalling systems (such as those involving endogenous opioids and hypothalamic signalling molecules, among others).

The rewarding effects of cannabinoid receptor activation are underscored by the fact that cannabis is one of the most widely used illicit substances worldwide. Δ⁹-THC is the primary psychoactive constituent in cannabis and exhibits low efficacy as an agonist at CB1R and CB2R. In animal models, both Δ⁹-THC and synthetic CB1R agonists enhance brain reward function (as indexed by intracranial self-stimulation), produce rewarding effects in the paradigm of conditioned place preference (CPP) and are voluntarily self-administered (intravenously and also directly into the NAc shell and posterior VTA). These effects are critically reliant on CB1R signalling and are highly dose-sensitive, with a rapid shift to negative-reinforcing effects with increasing dose.

In contrast to exogenous cannabinoid receptor agonists, pharmacological enhancement of eCB levels generally does not produce rewarding effects per se. For example, in most animal studies, selective eCB-clearance inhibitors do not support operant self-administration, do not produce CPP and do not alter brain stimulation reward thresholds in rats and mice. Similarly, exogenously administered AEA or 2-AG, or selective FAAH or MAGL inhibitors, do not produce Δ⁹-THC-like discriminative stimulus effects. However, exogenous AEA and 2-AG both support operant self-administration in squirrel monkeys and produce rewarding and Δ⁹-THC-like effects in rats when they are administered after eCB-clearance inhibition. Concurrent FAAH and MAGL inhibition in mice produces Δ⁹-THC-like discriminative stimulus and behavioural effects. These findings suggest that robust engagement of eCB signalling is needed to evoke rewarding effects. However, recent evidence indicates that squirrel monkeys with a history of AEA, nicotine or cocaine self-administration will self-administer the FAAH inhibitor URB694, although this compound does not produce Δ⁹-THC- or nicotine-like discriminative stimulus effects and does not increase mesolimbic DA release. Although it remains to be determined whether URB694 will be self-administered by drug-naive monkeys or other species, this observation indicates that FAAH inhibition is not aversive and may produce mildly rewarding effects.

Cannabinoid receptor involvement in non-cannabinoid drug reward. The presence of CB1Rs throughout brain reward circuits and the rewarding effects produced by CB1R activation allow for the possible influence of eCB signalling on the acute rewarding effects produced by non-cannabinoid substances (the effects of CB1R and FAAH manipulations on non-cannabinoid drug reward are summarized in Table 1). In general, drugs that activate CB1Rs do indeed seem to facilitate the rewarding effects of non-cannabinoid drugs. CB1R agonists increase the motivational and reinforcing effects of alcohol, nicotine and opiates, as indexed by animal models of drug reward (including the CPP and operant self-administration assays), whereas diminished

---

**Figure 2** Distribution of endocannabinoid signalling mechanisms within the brain reward circuits. Cannabinoid 1 receptors (CB1Rs) are expressed throughout the regions implicated in reward and addiction, including the basolateral amygdala (BLA), prefrontal cortex (PFC), hippocampus (HIPP), ventral pallidum (VP), globus pallidus (GP), dorsolateral striatum (DLStr), nucleus accumbens (NAc), ventral tegmental area (VTA), bed nucleus of the stria terminalis (BNST) and central nucleus of the amygdala (CeA). In general, the expression patterns of endocannabinoid (eCB)-biosynthetic enzymes (for example, N-acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD) and 1,2-diacylglycerol lipase-α (DAGLα) and hydrolytic eCB-clearance enzymes (for example, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)) are similar to those for CB1Rs across the regions depicted here. Within the amygdala, CB1R, DAGLα, MAGL and FAAH expression is highest in the lateral and basolateral nuclei, with substantially lesser expression in the CeA. In the dorsal striatum, there is a comparable mediolateral gradient of CB1R and DAGLα expression, with greater levels of expression evident in lateral aspects. Comparatively weaker CB1R, DAGLα and FAAH expression is observed in the NAc. Although little to no CB1R expression is found in dopamine cells in the NAc, DAGLα has been found in both dopaminergic and non-dopaminergic cells in this region. CB1R and FAAH manipulations on non-cannabinoid drug reward are summarized in Table 1. In general, drugs that activate CB1Rs do indeed seem to facilitate the rewarding effects of non-cannabinoid drugs. CB1R agonists increase the motivational and reinforcing effects of alcohol, nicotine and opiates, as indexed by animal models of drug reward (including the CPP and operant self-administration assays), whereas diminished...
CB1R signalling (through either genetic deletion or pharmacological antagonism) attenuates the motivational and rewarding effects of these drugs\textsuperscript{11,25,26}. The effects of CB1R antagonism on alcohol and nicotine reward result in part from a diminished ability of these drugs to increase NAc DA release\textsuperscript{27}. Blockade of CB1Rs specifically in the VTA decreases alcohol and nicotine self-administration\textsuperscript{28,29}, and blockade of CB1Rs specifically in the NAc reduces alcohol consumption\textsuperscript{26,30}. However, whereas nicotine reward is critically dependent on the mesolimbic DA system\textsuperscript{11}, the motivational and rewarding effects of alcohol and opiates are less
Table 1 | Summary of CB1R and FAAH influences on non-cannabinoid drug reward

<table>
<thead>
<tr>
<th>Genetic or pharmacological manipulation</th>
<th>Drug</th>
<th>Opiates</th>
<th>Stimulants</th>
</tr>
</thead>
<tbody>
<tr>
<td>CB1R knockout</td>
<td>ETH</td>
<td>CPP</td>
<td>CPP</td>
</tr>
<tr>
<td>CB1R antagonist</td>
<td>CPP</td>
<td>CPP</td>
<td>CPP</td>
</tr>
<tr>
<td>CB1R agonist</td>
<td>CPP</td>
<td>CPP</td>
<td>CPP</td>
</tr>
<tr>
<td>FAAH inhibition</td>
<td>CPP</td>
<td>CPP</td>
<td>CPP</td>
</tr>
</tbody>
</table>

CB1R, cannabinoid 1 receptor; CPP, conditioned place preference; DA, dopamine; FAAH, fatty acid amide hydrolase; ICSS, intracranial self-stimulation (an index of brain reward function); NAc, nucleus accumbens; VTA, ventral tegmental area.

DA-dependent\(^{22,23}\), and the CB1R modulation of the rewarding effects of these drugs probably involves non-dopaminergic mechanisms. Indeed, CB1R antagonism does not alter opiate-induced increases in NAc DA levels but reduces opiate reward through the prevention of opiate-induced reductions in ventral pallidal GABA release\(^ {24}\). In comparison to these drugs, CB1R manipulations on psychostimulant reward have modest and less-consistent effects. CB1R agonists reduce the facilitation of brain stimulation reward produced by cocaine and reduce cocaine self-administration\(^ {16,34}\). Most reports indicate that CB1R antagonism does not affect psychostimulant reward (as assessed by cocaine-induced enhancement of brain stimulation reward, CPP and self-administration) or cocaine-induced increases in NAc DA levels\(^ {27}\) (but see REFs \(^ {27,37}\)).

Recent evidence in mice also implicates CB2Rs in the modulation of drug reward, including an inhibitory influence on cocaine and alcohol reward\(^ {18,19}\) but a facilitatory influence on nicotine reward\(^ {40,41}\). However, disparate observations have been made in rats\(^ {30,42,43}\), and it is possible that these findings are influenced by species differences in CNR2 splicing that confer distinct CB2R structure, function or pharmacology\(^ {39}\).

**Alterations in brain eCB levels elicited by drugs of abuse.** Given the on-demand nature of eCB production and the associated modest eCB signalling tone under baseline conditions, the robust influence of cannabinoid receptor signalling on non-cannabinoid drug reward has led to the hypothesis that drug exposure increases brain eCB formation. Substantial evidence demonstrates that there are alcohol-induced alterations in post-mortem eCB content in the rodent brain, although inconsistencies among studies cloud definitive conclusions regarding the direction of change and the regional nature of the effects\(^ {44}\). For example, alcohol exposure increases extracellular 2-AG levels in rat NAc (measured by in vivo microdialysis), and this is more pronounced following voluntary self-administration than after non-contingent alcohol exposure\(^ {28,29}\). By contrast, extracellular AEA levels in the NAc are unaltered by alcohol self-administration and are decreased by non-contingent alcohol administration. Alcohol also seems to induce region-specific changes in brain-tissue eCB levels, with alcohol-induced disruptions being consistently observed in striatal regions\(^ {30,43,46}\) but not in frontal cortical areas\(^ {37}\). This is consistent with evidence that alcohol consumption is reduced by CB1R antagonism in the VTA and NAc but not in the PFC\(^ {28,30,47}\).

Similarly to alcohol, nicotine alters eCB levels in the rodent brain, with factors such as the brain region evaluated and the voluntary nature of drug exposure having important relevance to the effects observed. Repeated non-contingent nicotine injections increase AEA levels in rat limbic forebrain and dorsal striatal tissue but decrease both AEA and 2-AG levels in cortical tissue\(^ {48}\). Intravenous nicotine self-administration increases extracellular levels of both AEA and 2-AG in the rat VTA, and the effect on 2-AG is sensitized by chronic nicotine exposure\(^ {49}\). Interestingly, although VTA 2-AG levels are elevated by both voluntary and non-contingent nicotine exposure, VTA AEA levels are increased only by voluntary nicotine self-administration\(^ {50}\). Together with the evidence of distinct patterns of brain eCB levels induced by volitional versus non-contingent alcohol exposure\(^ {28,30}\), these data suggest that brain eCB production is influenced not only by drug-related pharmacological effects but also by neural activity engaged by active drug self-administration (possibly related to the motivation for drug consumption).

Relatively less is known regarding the effects of other rewarding drugs on brain eCB levels. Available evidence consistently indicates that opiates increase AEA but decrease 2-AG tissue concentrations in the striatum, limbic forebrain and hippocampus\(^ {50,51}\). Similarly, heroin self-administration increases extracellular AEA with a concomitant decrease of extracellular 2-AG levels in the...
rat NAc. Psychostimulants generally produce modest disruptions in brain eCB content, with subtle increases and decreases in 2-AG concentration in forebrain following non-contingent acute and chronic cocaine exposure, respectively (no other alterations are evident regardless of region analysed). Moreover, voluntary cocaine self-administration does not alter rat extracellular NAc eCB levels but decreases 2-AG content in frontal cortex and hippocampal tissue.

Collectively, these findings indicate that alcohol, nicotine and opiates alter brain eCB content, consonant with the CB1R influence on the behavioural effects produced by these drugs. The generally modest effects of psychostimulants on brain eCB levels are in-line with the subtle CB1R influence on psychostimulant-induced behaviours. Similarly to that seen with multiple biological conditions, drug exposure often produces distinct and sometimes opposite effects on brain AEA and 2-AG levels. This suggests differential regulation of the synthesis and/or degradation of these eCB moieties at specific synapses that may arise from the segregation of MAGL and FAAH in the pre- and postsynaptic compartments, or the hypothesized role of AEA and 2-AG in regulating ‘tonic’ and ‘phasic’ signalling in the ECS, respectively. Although a general picture of drug-induced alterations in brain eCB levels is emerging, experimental differences between studies — including the drug dose used, the method of drug exposure and the duration of treatment — make it difficult to draw strong conclusions, and additional studies are warranted.

Influence of eCB tone on drug reward. eCBs are rapidly degraded, so strategies that reduce eCB clearance have been used as a means to further investigate the eCB influence on drug reward. Most investigations have focused on the effects of FAAH inhibition, because selective tools for inhibiting MAGL and other eCB-clearance enzymes were not available until recently. Such studies have shed light on important species differences that confound the overall conclusions that can be made from existing data. For example, FAAH inhibition in mice increases nicotine reward in the CPP paradigm, but FAAH inhibition in rats prevents nicotine-induced CPP; diminishes nicotine self-administration and blunts nicotine-induced increases in NAc DA release. The potentiation of nicotine reward in mice by FAAH inhibition is CB1R-mediated, whereas the reduction in nicotine reward in rats results from activation of PPARα by non-cannabinoid lipids, such as oleoylethanolamide and palmitoylethanolamide, that are hydrolytically cleared by FAAH. FAAH inhibition also produces distinct species-related alterations in alcohol consumption, with increased intake being observed in mice but not in rats. The mechanisms underlying these differences are not understood. Brain region-specific disruptions in FAAH activity may be an important factor. In regard to alcohol reward, inhibition of FAAH activity specifically in the PFC results in increased alcohol consumption, and rats selectively bred for high alcohol intake and preference are characterized by reduced FAAH activity specifically in the PFC. The effects of FAAH inhibition on opiate and psychostimulant reward have primarily been studied in rats. FAAH inhibition does not alter morphine- or cocaine-induced disruptions in VTA DA-cell firing or the self-administration of either drug. However, FAAH inhibition diminishes cocaine-induced alterations in NAc medium-spiny neuron activity, and this may contribute to enhanced sensitization of both cocaine-induced motor activity and mesolimbic DA responses following repeated cocaine exposure. Other studies have investigated the effects of putative eCB transport inhibitors, such as AM404 and VDM11, and the findings thus far suggest that these compounds produce subtle and inconsistent effects on nicotine and cocaine reward.

Although growing evidence implicates ECS influences in the modulation of acute drug reward, additional efforts are needed to further clarify the nature of eCB disruptions caused by different classes of abused drug and the neural mechanisms through which these eCB influences are mediated. Selective inhibitors of 2-AG clearance have recently been developed, but studies using them are still in their infancy and there are presently no published reports on the effects of enhanced 2-AG tone on drug reward and related physiological events. As such, there remains a substantial gap of knowledge, given the prominent 2-AG influence on neural signalling and plasticity related to both drug and natural rewards. Nevertheless, the role of the CB1R in drug reward is unequivocal and, although there is evident complexity related to the effects produced by eCB-clearance inhibition (producing discrete modulation of eCB tone in specific synapses and circuits when compared with broad CB1R activation by exogenous CB1R agonists), the extant evidence strongly supports an eCB influence on the sensitivity to, and motivation for, several drugs of abuse.

ECS signalling in addiction

Numerous factors influence the transition from intermittent, controlled drug use to the compulsive forms of drug-seeking and drug-taking behaviour that characterize addiction. Substantial evidence implicates genetic influences in the development of substance-use disorders (SUDs) and pathological forms of eating, sexual behaviour and gambling, and it is increasingly recognized that epigenetic mechanisms drive lasting changes in addiction-related gene expression. Long-term drug exposure induces lasting neuroadaptations in motivational mechanisms that propel drug-seeking behaviour and drug use. Although initial drug use is motivated by hedonic processes, prolonged drug exposure progressively blunts reward system function, thereby leading to escalated frequency and amount of drug consumption, resulting in a dependent state wherein negative affective symptoms (for example, dysphoria, anxiety and irritability) emerge during abstinence. These negative emotional states arise from the recruitment of stress signalling systems (such as corticotropin releasing factor and dynorphin) and dysregulation of mechanisms that constrain these responses (such as neuropeptide Y and nociceptin) within the extended amygdala. Renewed drug consumption alleviates these negative affective states, and this is
Conditioned reinforcement
The process through which neutral stimuli acquire motivational properties through association with a primary reinforcer.

Stochastic optical reconstruction microscopy
A super-resolution imaging technique that uses sequential activation and time-resolved localization of photoswitchable fluorophores to create high-resolution images enabling precise fluorophore localization with nanometre resolution.

Conceptualized to motivate compulsive drug use through negative reinforcement. Superimposed on these processes is a dysregulation of corticostriatal mechanisms mediating stimulus–response learning, constraint of impulsivity, conditioned reinforcement and incentive motivation, resulting in a narrowed focus on drug-seeking at the expense of natural rewards.

eCBs exert prominent modulatory influence on the extended amygdala and corticostriatal circuits and, increasing evidence suggests that pre-existing genetic influences on the ECS and/or drug-induced dysregulation of eCB function participate in the development and maintenance of addictions, including pathological forms of eating. The following sections consider the consequences of chronic drug exposure on eCB signaling within the reward circuitry and related disruptions in synaptic plasticity, affective state and learning and memory mechanisms related to extinction and relapse. Finally, evidence is discussed for an influence of innate disruptions in ECS function (eCB gene polymorphisms) as vulnerability factors for substance abuse and addictive disorders in humans.

Chronic drug exposure and eCB function.
It is unsurprising that chronic cannabis use disrupts brain cannabinoid receptor availability and function. Using the in vivo technique of positron emission tomography (PET) imaging, one study reported that there was downregulation of brain CB1Rs in daily cannabis users, that the level of downregulation correlated with the number of years of cannabis use and that this downregulation was reversed after 1 month of monitored abstinence. Another PET study reported a global reduction in CB1R availability driven by differences in the temporal lobe, anterior and posterior cingulate cortex and NAc. Similarly, animals given non-contingent chronic cannabinoid exposure exhibit decreased CB1R function throughout the brain. Recent experiments using stochastic optical reconstruction microscopy demonstrate that chronic exposure to clinically relevant doses of Δ⁹-THC results in a startling loss of CB1Rs on terminals of perisomatically projecting GABAergic interneurons in the mouse hippocampus and internalization of the remaining CB1Rs. The resulting deficits in inhibitory CB1R control over hippocampal GABA release persisted during several weeks of Δ⁹-THC abstinence, and this may underlie the enduring loss of hippocampal long-term potentiation (LTP) in rodents and memory deficits in humans evident following chronic cannabinoid exposure.

Surprisingly little is known of the effect of chronic cannabinoid exposure on other facets of ECS function. Chronic cannabinoid exposure increases enzymatic clearance of AEA and reduces brain tissue AEA content in rodents and frequent cannabis smokers present decreased AEA and increased 2-AG levels in blood, although increased serum AEA levels are evident following at least 6 months of cannabis abstinence. The contribution of these disruptions to cannabis-use disorder and related physiological and behavioural disruptions is presently unexplored. However, as discussed below, eCBs provide important homeostatic constraint over emotional state and sleep function, and it is conceivable that Δ⁹-THC-induced impairment of eCB signaling contributes to the negative emotional states and sleep disturbances present during protracted cannabis abstinence.

Several findings support the hypothesis that chronic exposure to non-cannabinoid drugs disrupts eCB signaling and processing. Chronic alcohol exposure in rodents alters eCB-related gene expression in a manner sensitive to the intermittent nature of alcohol exposure and post-alcohol abstinence period and downregulates CB1R expression and function. Post-mortem studies of alcohol-dependent humans also demonstrate disrupted CB1R expression in the ventral striatum and cortical regions, and in vivo imaging studies demonstrate decreased CB1R availability in heavy-drinking alcoholics that persists for at least 1 month of abstinence (but see Ref. 96). Although a potential contribution of variants of CNR1 (which encodes CB1R) to these observations cannot be excluded, a common interpretation based on animal studies is that these CB1R adaptations in humans with alcoholism are a consequence of prolonged alcohol-induced increases in brain eCB levels. This is supported by evidence of transient recovery (and perhaps eventual upregulation) of CB1R function in humans during protracted alcohol abstinence.

In rodents, chronic nicotine exposure induces distinct age-related disruptions in CB1R binding, with increased levels being evident in the PFC, VTA and hippocampus.
of adolescent, but not adult, rats and increased hippocampal and decreased striatal CB1R binding being seen in adult rats during protracted nicotine abstinence. Few studies have investigated altered CB1R binding following chronic opiate or psychostimulant exposure, but findings in rodents implicate impaired CB1R function in the development and expression of opiate dependence and demonstrate that chronic cocaine use increases CB1R binding in the dorsal striatum, NAc and cortical areas. Interestingly, detoxified cocaine addicts present significant increases in plasma AEA and decreases in plasma 2-AG content, but the functional consequence of these disturbances is not known. Overall, accruing data suggest that long-term exposure to various drug classes compromises eCB processing and CB1R expression and function. As discussed below, these perturbations may contribute to aberrant neural signalling during acute and protracted drug abstinence.

Addiction-related synaptic plasticity. The development and persistence of addiction is attributed to maladaptive synaptic plasticity evidenced in the neuronal reorganization (molecular, cellular and functional activity) of mesocorticolimbic and striatal pathways. eCB signalling at CB1Rs is implicated in several forms of synaptic plasticity, most commonly in depolarization-induced suppression of excitatory transmission (DSE) or inhibitory transmission (DSI), short-term depression (STD) and long-term depression (LTD); a prolonged form of weakened synaptic strength. STD, DSE and DSI are mediated primarily by 2-AG signalling, typically persist for a minute or less, and have been observed in brain areas relevant to reward and addiction, including the VTA, basolateral amygdala, hippocampus, neocortex and substantia nigra. By comparison, eCB-mediated LTD can persist for hours or weeks, is particularly important in learning and memory, and has also been observed in addiction-related regions, including the NAc, VTA, amygdala, PFC, hippocampus and dorsal striatum.

Acute and chronic alcohol exposure reduces CB1R-dependent plasticity, resulting in long-lasting disinhibition of striatal output neurons and diminished eCB-mediated LTD (eCB-LTD) at inhibitory striatal synapses. Because the dorsal striatum mediates reward-guided learning and habitual behaviour, these eCB disruptions may contribute to maladaptive habitual behaviour that perpetuates addiction. Cocaine diminishes eCB-LTD of excitatory transmission in the NAc and facilitates eCB-LTD of inhibitory signalling at VTA DA synapses, resulting in diminished inhibitory control over VTA DA-cell activity and heightened excitatory signalling in the NAc. Cocaine also disrupts CB1R-LTD of excitatory transmission in the BNST, a component of the extended amygdala, and this may contribute to aberrant stress-reward interactions (via projections to the VTA) and excessive anxiety-like behaviour. Similarly, chronic Δ-THC or synthetic CB1R agonist exposure abolishes eCB-LTD of excitatory and inhibitory signalling in the NAc and hippocampus, which may significantly affect reward processing mediated by these regions. Little is known regarding opiate- or nicotine-induced disruptions in eCB-mediated synaptic plasticity, although cue-induced reinstatement of nicotine-seeking behaviour (an animal model of relapse) relies in part on the induction of CB1R-mediated LTD of cortical synapses in the BNST. Thus, chronic drug exposure disrupts eCB-mediated forms of synaptic plasticity in several regions involved in reward processing. As discussed below, impaired eCB-mediated plasticity may also contribute to dependence-related affective disruptions that serve to sustain drug dependence.

Withdrawal-related affective disruption. Stress has a prominent role in the development of addiction, and stress exposure disrupts eCB-mediated plasticity in regions that participate in emotional control, including the NAc, amygdala and BNST. Withdrawal from most drugs of abuse is associated with increased stress responsivity and persistent negative affective symptoms, such as anxiety and depression, the severity of which are closely associated with relapse susceptibility. Comorbidity of affective disorders and SUDs is prevalent, and pre-existing negative affective traits may be an antecedent to addiction. The ECS participates in a negative-feedback system that constrains emotional distress under stressful circumstances and contributes to the suppression of aversive memories. This function is reliant on eCB-mediated forms of synaptic plasticity, and deficient eCB signalling is associated with increased anxiety and depression. As such, impaired eCB function may contribute to negative affective states and increased stress responsivity that underlie negative-reinforcement mechanisms driving drug use by dependent individuals and that contribute to drug relapse following periods of abstinence.

Mice lacking CB1Rs exhibit greater anxiety-like behaviour than normal animals during nicotine withdrawal, although innate anxiety-like behaviour in the knockout mice clouds interpretations. Studies evaluating eCB-clearance inhibition provide more direct insight into withdrawal-related eCB disruption and negative affect. Acute FAAH inhibition reverses enhanced anxiety-like behaviour that is normally present during both nicotine and alcohol withdrawal, and the eCB-transport inhibitor AM404 attenuates depression-like behaviour during nicotine withdrawal. Post-traumatic stress disorder is particularly prevalent among individuals with alcohol-use disorders, and this is often modelled in rodents using the fear-conditioned startle paradigm to study reflexive physiological reaction to a stimulus. Rodents selectively bred for high alcohol consumption exhibit greater fear-potentiated startle than corollary lines bred for low alcohol consumption. In addition, acute FAAH inhibition by LY2183240 reduces fear-potentiated startle in high alcohol-prefering, but not low alcohol-prefering, mice, consistent with the efficacy of FAAH inhibition for accelerating the extinction of aversive memory. LY2183240 also enhances the conditioned rewarding effects of alcohol without altering alcohol consumption itself, suggesting that FAAH...
inhibition influences memory-related processes (conditioned fear and conditioned alcohol reward) in animals predisposed towards high alcohol consumption.

**Addiction-related learning and memory**

Both positive and negative memories and conditioned cues associated with drug use perpetuate drug-seeking behaviour and the continued cycle of abuse. The ECS has a prominent role in learning and memory processes, and CB1R signalling is strongly linked to the conditioned rewarding effects of alcohol, nicotine and opiates. Although drug-induced conditioning effects are generally interpreted in the context of drug reward, a CB1R influence on the associative learning aspects of drug exposure is also possible, which as discussed below may have relevance to the persistent reactivity to drug-related memories that characterizes addiction.

**Drug-seeking (relapse).** Drug exposure produces powerful interoceptive effects that become associated with environmental cues, such that these cues alone can induce craving and promote relapse following periods of abstinence. In addition to conditioned drug memories, acute exposure to a preferred drug or pharmacologically related agent (that is, drug priming) and stressful events can precipitate relapse.

Animal models of relapse demonstrate an important cannabinoid influence on the reinstatement of extinguished drug-seeking and drug-taking behaviours. Δ⁹-THC and synthetic CB1R agonists reinstate drug-seeking for cannabinoids, alcohol, nicotine, opiates and cocaine, whereas CB1R antagonists attenuate drug-seeking behaviour associated with each of these drugs. CB1Rs in the PFC and NAc shell influence cue-induced reinstatement of both heroin- and nicotine-seeking behaviour, whereas CB1Rs in the basolateral amygdala contribute to cue-induced nicotine- but not heroin-seeking behaviour. Despite the subtle effects of CB1R inactivation on psychostimulant self-administration, CB1R antagonism attenuates drug-prized, cue-induced and some forms of stress-induced reinstatement of cocaine- and methamphetamine-seeking behaviour in...
rats. Thus, CB1R signalling modulates drug-seeking for various pharmacologically distinct drugs. There is also evidence that CB1R antagonism blocks both cue- and priming-induced reinstatement of seeking behaviour for non-drug rewards, such as sucrose and corn oil (but see ref. 134). Accordingly, CB1R signalling seems to participate in the modulation of conditioned reward in general.

Drug-primed and cue-induced nicotine- and cocaine-seeking behaviour are reduced following acute FAAH inhibition that leads to elevated AEA levels25,56, which may be surprising considering that CB1R agonists enhance both nicotine- and cocaine-seeking behaviour23. However, inhibition of eCB clearance probably amplifies eCB signalling preferentially in circuits or synapses activated by a given stimulus (in this case, drug-seeking behaviour), rather than inducing more widespread indiscriminate CB1R activation, as produced by exogenous CB1R agonists. Moreover, FAAH hydrolyses a large range of fatty acid moieties, and the effects of FAAH inhibition on drug-seeking behaviour may involve non-cannabinoid lipid signalling. In this regard, it is notable that the eCB transport inhibitor VDM11 attenuates both nicotine- and cue-induced nicotine-seeking behaviour11, and this compound may preferentially block AEA clearance with weaker effects on non-cannabinoid lipids135,136. Similarly, the eCB transport inhibitor AM404 dose-dependently attenuates nicotine- and cue-induced nicotine-seeking behaviour without altering nicotine self-administration22.

In contrast to nicotine- and cocaine-seeking behaviour, neither FAAH inhibition nor eCB transport inhibition alter cue- or stress-induced reinstatement of alcohol-seeking behaviour65,137. However, studies in humans with alcoholism suggest a relationship between eCB tone and craving that may relate to the degree of dependence and possibly inherent factors contributing to alcoholism vulnerability. In social drinkers, alcohol-related cues increase both craving and plasma AEA levels, and the relative magnitude of cue-induced increases in AEA is significantly correlated with the degree of craving138. However, recently detoxified individuals with alcoholism present significantly lower baseline plasma AEA levels than non-dependent social drinkers and, although alcohol-related cues elicit more-intense cravings in alcoholics, these individuals do not present significant cue-induced increases in plasma AEA. This blunted AEA response may reflect aberrant eCB processing in people with alcoholism, but further investigations are needed to confirm a direct link between this potential peripheral biomarker and brain eCB signalling, as well as possible causal relationships between dysregulated eCB processing and behaviour.

Extinction learning. The potent motivational effects of drug-related cues create substantial difficulties during periods of attempted drug abstinence and are causal in the reinstatement of drug intake (for example, relapse)137. One approach for reducing the motivational impact of drug-associated cues is through extinction training, in which a subject learns that these cues no longer have predictive value. However, extinction therapy is generally ineffective for reducing relapse in both humans139 and rodents140, and it is conceivable this is a consequence of diminished learning mechanisms required to override the original cue-association memory. The ECS has a prominent role in memory extinction, and deficient CB1R signalling results in impaired extinction of cued fear memory, contextual fear memory, fear-potentiated startle and spatial memory under mildly aversive conditions141,142. Moreover, as previously noted, FAAH inhibition facilitates the extinction of fearful memory in mice selectively bred for high levels of alcohol preference and consumption143. Because aversive memory may be involved in relapse to drug taking144, deficient eCB signalling following long-term drug exposure may contribute to the limited efficacy of extinction therapy for addiction.

eCB gene polymorphisms and addiction

Approaches to explore the contribution of the ECS to addiction disorders in humans often involve heritability considerations, as it is now acknowledged that genetics plays an important part in drug addiction vulnerability, accounting ~30–80% for risk depending on the drug class144,414. Based on the growing evidence of a role for the ECS in regulating reward, mood and cognition and owing to its prominent expression within neuronal systems related to these functions, the ECS has been viewed as a central target for candidate-gene studies of addictive disorders. Similarly to the preclinical animal studies described above, most investigations have focused on CNR1 and FAAH46,147, Consistent with most genetic investigations, important confounding factors include race, ethnicity, type of drug, polysubstance use and population sample size. Nevertheless, although they are not all equivocal, what can be garnered from existing genetic studies (although limited) suggests that genomic heterogeneity of the eCB-related genes may influence in part substance abuse vulnerability and relate to behavioural and pathophysiological traits that are highly associated with addictive disorders in humans (FIG. 5).

CNR1. Human CNR1 is located on chromosome 6 (6q14-q15), with the coding region situated at the 5’-end of exon 4. Several different CNR1 isoforms vary in expression across brain regions, although each of the main mRNA variants expresses the same exon 4 that encodes the CB1R protein148. Indeed, CNR1 exhibits substantial functional conservation, with few common missense variants in the CB1R protein being expressed148.

One of the first CNR1 variants explored in relation to drug abuse was the AAT-triplet repeat ((AAT) n) microsatellite polymorphism in the 3’-untranslated region, located close to the exon 4 translational start site148. Unfortunately, direct functional evidence is lacking to understand its relevance to eCB processing, but the increased number of repeats is speculated to result in reduced CB1R expression149. Increased frequency of long (AAT) n was initially observed in an intravenous drug-dependent non-Hispanic US white population150, and this was partially supported in subsequent evaluations of Afro-Caribbean individuals151. Some reports
failed to replicate the original finding, but a meta-analysis of multiple variants of CRN1 in white populations specifically identified the (AAT) polymorphism as the only significant association with illicit SUDs. Interestingly, the (AAT) polymorphism has been linked with reduced amplitude of the frontal lobe P300 event-related brain potential, a disruption that has been suggested as a neurobiological endophenotype of impaired cortical processing in drug abusers.

Additional single nucleotide polymorphisms (SNPs) of CRN1 have been investigated, the most frequent of which is a silent intragenic biallelic polymorphism (G1359A; rs1049353). This exon 4 synonymous mutation does not change the amino acid sequence of the mature protein, but the SNP is speculated to affect mRNA stability or protein translation in a way that could alter CB1R function. Several investigations, although not all congruent, suggest an association of the CRN1 G1359A polymorphism with substance abuse. For example, the A-allele is associated with severe alcoholism, specifically in relation to enhanced withdrawal delirium in white patients and enhanced impulsivity in Native Americans with a high lifetime prevalence of substance dependence. The G1359A variant has also been associated with heroin abuse in a white population, but with the A-allele conferring protection and the G/G genotype conferring addiction risk. Additional studies are clearly needed to determine whether the risk-versus-protection profile might depend on the drug class.

Aside from the G1359A SNP, most of the other CRN1 variants reported to be associated with addiction are not within the coding region; this is not surprising, considering that it is now evident that most variation in the genome falls outside protein-coding regions. The rs2023239 variant, representing a T to C polymorphism in the intronic region upstream of exon 3, has been shown to relate to CB1R levels measured in post-mortem brain tissue and in vivo using PET imaging, with the C-allele being associated with enhanced CB1R levels in the normal human brain. As discussed above, increased CB1R in animal models is predictive of addiction vulnerability and, indeed, the rs2023239 SNP has been linked to a general liability for substance abuse. Individuals with the C-allele use greater amounts of cannabis, exhibit higher cannabis dependency and experience greater negative affect and craving for cannabis following withdrawal.

The rs2023239 minor allele also associates with increased activation in reward-associated brain areas (as measured by blood oxygenation level-dependent (BOLD) imaging) to cannabis-related cues. Individuals with the A-allele carriers have also enhanced alcohol cue-elicited brain activation in the PFC, NAC and midbrain (consistent with the VTA and surrounding regions), greater subjective reward when consuming alcohol, a strong correlation between cue-elicited brain activation and alcohol consumption measures, and a strong association with alcohol-use disorder and craving measures.

Several CRN1 haplotype blocks have also been linked with addiction. When analysed as a haplotype (TAG), three SNPs (rs806379, rs1535255 and rs2023239) in the distal region of intron 2 of the CRN1 gene were significantly associated with polysubstance abuse in adults from different ethnicities. Moreover, Agrawal et al. demonstrated an association between a CRN1 haplotype and cannabis dependence (the majority of these individuals also met criteria for alcohol dependence). The rs806380 SNP proximal to the TAG haplotype has also been linked with the development of cannabis-dependence symptoms (protective effect of G-allele). Other haplotypes have been reported to associate with either low (rs6454674, rs806380, rs806377 and rs1049353: GGCC) or increased (TACC and GACC) risk for cannabis dependence. However, inconsistent and nominal significance has been reported in replication studies of cannabis dependence in adolescent and young adult populations and for other haplotypes in substance abuse populations. Overall, although the majority of genetic investigations suggest...
Box 2 | Endocannabinoid influence on epigenetic mechanisms

Epigenetic influences are functionally relevant changes to the genome that do not involve disruptions in the nucleotide sequence of DNA. Examples of epigenetic mechanisms include DNA methylation, post-translational histone modification, nucleosome positioning and silencing associated with small non-coding RNAs (such as microRNAs and small interfering RNAs). Recent evidence demonstrates that epigenetic factors can regulate the expression of endocannabinoid (eCB)-related genes and that FAAH may themselves induce epigenetic alterations49. For example, DNA hypermethylation of CNR1 (the gene encoding cannabinoid 1 receptor (CB1R)) results in downregulation of transcription in the CNS and immune system, whereas decreased DNA methylation can result in increased fatty acid amide hydrolase (FAAH) transcription; these processes have been implicated in several pathologies, including colon cancer and late-onset Alzheimer disease. Conversely, eCB-induced alterations in enzymes influencing histone modification may disrupt the transcription of several genes, including those encoding various neurotransmitter systems. In rodents, early life stress (maternal separation) is associated with elevated DNA methylation of the CNR1 promoter194, which, through a resultant decrease in CB1R expression, could contribute to affective dysregulation and addiction susceptibility later in life. Several studies implicate increased epigenetic influences following chronic Δ9-tetrahydrocannabinol (Δ9-THC) exposure. Cannabis-dependent patients present robust methylation of the CNR1 promoter in association with diminished CNR1 mRNA in peripheral blood cells196. Furthermore, offspring of maternal cannabis users exhibit histone methylation and dysregulated mesolimbic dopamine D2 receptor expression197, and adolescent Δ9-THC exposure is associated with nucleus accumbens (NAC) chromatin modifications and concurrent upregulation of the opioid neuropeptide proenkephalin gene198. Prenatal alcohol exposure increases expression of the regulatory microRNA mir-26b (which targets the 3’-untranslated region of the CNR1 transcript) and decreased CNR1 transcription in the adult mouse brain199. Thus, growing evidence suggests that there are eCB-related epigenetic influences following drug exposure.

an association between CNR1 variants and aspects of SUDs, the data are not definitive and no causative loci have been described to date. What seems most consistent in the human genetic studies is a relevance to drug cue sensitivity and craving, which would complement the preclinical animal studies that demonstrate their direct link to the ECS.

FAAH. Few genetic investigations have focused on other components of the ECS, with FAAH being the second gene most-often studied in relation to addiction, based on AEA's important functional role. Human FAAH is located on chromosome 1p35-p34 and has 15 exons, with functional protein domains being encoded across multiple exons. A SNP that has been highly investigated is rs324420, which is located in exon 3 and results in a missense mutation of a C–A replacement at position 385, leading to a proline to threonine change at protein position 129 (REF. 166). This C385A SNP is functional and is thought to result in reduced FAAH expression and enzyme activity, such that individuals with the A/A genotype have enhanced plasma concentrations of AEA and other N-acylethanolamine FAAH substrates167. Although some studies have not observed associations between the C385A polymorphism and SUDs, existing evidence implicates this genetic disruption in addiction-related behaviours in different races and ethnicities167. Specifically, the A/A genotype associates with reduced vulnerability for cannabis dependence in white adults, whereas the C/C genotype associates with increased craving and negative affect during cannabis withdrawal. Initial studies failed to detect a link between the A/A genotype and alcohol or nicotine dependence168, although recently an over-representation of C/C carriers was observed among individuals consuming levels of alcohol that put them at increased risk of alcohol-related problems169. Carriers of the FAAH C385A SNP display increased ventral striatal reactivity associated with delay discounting, a behavioural index of impulsivity and reward sensitivity170 and a markedly decreased relationship between threat-related amygdala reactivity and trait anxiety, similar to patterns observed in individuals with high familial risk for alcoholism171. These findings suggest that dysregulation of FAAH function through the C385A polymorphism confers increased impulsivity and increased anxiety sensitivity.

Collectively, recent studies of CNR1 and FAAH genetic variants generally suggest an association with endophenotypes implicated in addiction susceptibility, including reward sensitivity, impulsivity and negative affect, consistent with preclinical evidence linking the ECS to such behaviours. Gene–gene interactions within the ECS may also be relevant to vulnerability, as there seem to be additive interactions between variants of the FAAH (C385A; rs324420) and CNR1 (rs2023239) genes, resulting in heightened neural responses in reward-related brain areas to cannabis cues and more-severe negative affect during cannabis abstinence159,160. Growing evidence of an eCB influence on epigenetic mechanisms suggests an additional but understudied way in which EC signalling may contribute to addiction (BOX 2). Clearly, a major confounding factor of most investigations to date is the small population size used, emphasizing the need for replication studies and studies using larger populations. The few existing agnostic genome-wide approaches have not identified eCB–related genes in relation to SUDs interrogated thus far. However, the contribution of endophenotypes along the continuum between genotype and drug-abuse phenotype has not been interrogated, despite the complex nature of non-Mendelian addictive disorders. The lack of systematic consideration of behavioural traits limits the possibility to understand the full repertoire of the ECS to individual vulnerability to addiction. Moreover, the functional consequences of the variants (causal or correlated) are unknown, which makes coming to definitive conclusions challenging.

Summary and future directions

Although enhancement of eCB levels does not produce rewarding effects per se, eCB signalling at cannabinoid receptors participates in the mediation and modulation of both natural and drug-induced reward. Brain eCB content is modulated by most drugs of abuse and natural rewards, and a robust CB1R influence on the motivation to consume distinct classes of abused drugs and the association of CNR1 polymorphisms with aberrant reward processing and addictive behaviours strongly implicate CB1Rs in the aetiology of addiction. Long-term drug use leads to neuroadaptive downregulation of eCB signalling resulting from diminished CB1R and/or CB2R function as well as possible disruptions in eCB biosynthesis and/or clearance. This blunting of eCB function may contribute to known susceptibility factors for relapse, namely, increased stress
responsivity, increased negative affect, inefficient extinction of drug-related memories and increased drug-seeking behaviour and drug craving. Recent preclinical evidence demonstrates the efficacy of eCB-clearance inhibitors for ameliorating these behavioural abnormalities, which might offer future therapeutic interventions for addiction disorders. Importantly, because eCBs are generally produced in a synapse-specific manner, eCB-clearance inhibitors may preferentially facilitate eCB signalling in specific circuits engaged by distinct stimuli (for example, stress- or drug-associated cues) and therefore could present fewer unwanted behavioural effects than are produced by exogenous agonists that produce widespread cannabinoid receptor activation.

Despite growing attention being given to the cannabinoid receptors, there are still notable gaps in our understanding of the eCB influence on reward and addiction. The ECS plays a prominent part in neuronal guidance and brain development and, as such, disruptions in eCB function at an early age probably have substantial consequences for adult brain function. This is underscored by increasing evidence of the long-term consequences of prenatal or adolescent cannabinoid exposure. Although the effects of early life exposure to non-cannabinoid drugs are well studied, the specific contributions of persistent drug-induced disruptions in eCB signalling on adult neural function and behaviour are not understood. Robust bidirectional interactions between the ECS and sex hormones are now recognized, but few studies have characterized possible sex differences in the eCB influence on reward function, addiction and cognitive processing. There are also substantial limitations in the interpretation and replication of genetic analyses of the eCB influence in addiction, owing to heterogeneity of the populations, drug classes, polysubstance use and even drug-use phenotypes examined. Large-scale future studies across different populations and drug classes will be critical to understanding the relative effect and causal nature of ECS-related genetic mutations in the vulnerability to addictive disorders. Filling these gaps of knowledge is critical, given the important need for scientific data to help guide current discussions and changes being made in marijuana-legalization policies.

This study was among the first to demonstrate that adolescent Δ9-THC exposure results in enhanced µ-opioid receptor signalling in the NAC, which contributes to increased heroin self-administration. One of the first studies to demonstrate a common CB1R–DA interaction contributing to the dopaminergic effects produced by abused substances with distinct pharmacological properties.


31. Provides the first in vivo evidence that voluntary self-administration of non-cannabinoid drugs produces drug-specific and dose-related alterations in extracellular AEA and 2-AG levels in the rat NAC.


Provides the first evidence that FAAH inhibition reduces nicotine reward in rats. This finding led to a series of studies that stimulated PPARα receptors by FAAH substrates, including oleoylthanolamide, prevents nicotine-induced acquisition of rats in sustained non-human primates (these collective studies are reviewed and discussed in reference 61). Malis, M. & Pistis, M. Targeting the interaction between fatty acid amide hydrolase and nicotinic receptors: therapeutic perspectives. Pharmacol. Res. 86, 62–69 (2014).


Provides the first in vivo evidence of regionally selective down-regulation of brain CB1 receptors in human cannabis smokers.


Uses nanoscale imaging and electrophysiological techniques to demonstrate that there is greater CB1 expression and CB1-dependent current projection versus dendritically projecting GABA interneurons in the mouse hippocampus that persistent deficits in hippocampal LTP following chronic δ-tetrahydrocannabinol treatment emerge from near-complete loss of CB1R at somatic synapses.


References 113 and 114 were among the first to demonstrate that CB1 receptor blockade attenuates relapse-like behaviour in rats, thus blocking endocannabinoid-mediated synaptic plasticity. Nature Psychiatry 2, 161–171 (2017).


Provides detailed structural characterization of human CNR1, thereby providing information on splice variants and novel SNPs as well as evidence of a haplotype-specific association between CNR1 mRNA expression and alcohol abuse/dependence.


Supplies the first evidence for a strong influence of CB1Rs in the amygdala in the control of conditioned fear and reward, and related to fear, and this has led to critical insight into eCB-mediated reward, anxiety, and stress responses. Nature Neuroscience 18, 916–931 (2004).


Supplies the first evidence for a strong influence of CB1Rs in the amygdala in the control of conditioned fear and reward, and related to fear, and this has led to critical insight into eCB-mediated reward, anxiety, and stress responses. Nature Neuroscience 18, 916–931 (2004).


Supplies the first evidence for a strong influence of CB1Rs in the amygdala in the control of conditioned fear and reward, and related to fear, and this has led to critical insight into eCB-mediated reward, anxiety, and stress responses. Nature Neuroscience 18, 916–931 (2004).
REVIEWS


Leverages previous investigations to provide insights on CNR1 and FAAH gene interaction in association with marijuana use in the reward system in the mouse and rat models. The study emphasizes the additive genetic influence on cue reactivity as an intermediate endophenotype in cannabis abuse.


178. Trotman, A. et al. Brain mechanisms that control eCB release and regulation of mesolimbic (VTA) DA-neuron activity via the retrograde activation of presynaptic CB1Rs. This work set the model of eCB–DA interactions, in which increased DA–neuron burst firing is mediated through CB inhibition of VTA GABA cells (53, 54), thus leading to disinhibition of ventral tegmental area DA neurons.


186. Preserves the first in vivo evidence for interactions between the striatal DA system and eCB formation, which have substantial implications for several pathologies, including addiction and movement disorders.


Acknowledgements

This work was supported by grants from the US National Institute on Drug Abuse (DA00589, DA010460, DA018050). The authors thank D. Lewis for his help during the preparation of this manuscript.

Competing interests statement

The authors declare no competing interests.